“The fact that orexin can only affect plaques when it also affects sleep means we will have to think carefully about how to target it for Alzheimer’s prevention,” Holtzman said. “But the declines in plaque levels that we saw in the mice were very strong, so we’re still very interested in exploring its potential for reducing risk.” He and his colleagues, including first author Jee Hoon Roh, MD, PhD, currently are studying the effects of sleep medications on amyloid beta production and plaque accumulation. The FDA recently approved Belsomra, the first sleep medication that affects orexin, and the researchers hope to assess it or similar drugs in the future. Story Source: The above story is based on materials provided by Washington University School of Medicine . The original article was written by Michael C.
For the original version including any supplementary images or video, visit http://www.sciencedaily.com/releases/2014/11/141124092432.htm
Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division – Yahoo Finance
Prior to Molecular Devices, he managed a team of engineers at Affymax Research Institute, developing automated peptide and small molecule synthesis and compound-handling instruments. Bob holds a B.S. in Mechanical Engineering and an M.S.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/bio-techne-announces-appointment-robert-211500035.html